Former Electrophysiologist at Cleveland Clinic Brings Extensive Experience in

the Use of Interventional Magnetic Navigation Systems in the Treatment of

                            Cardiovascular Disease

ST. LOUIS, Jan. 17 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today the appointment of J. David Burkhardt, M.D., F.A.C.C., as Chief Medical Officer. Dr. Burkhardt was most recently the Associate Program Director for the Clinical Cardiac Electrophysiology Fellowship training program and he directed the Clinical Electrophysiology curriculum at the Lerner Case Western Reserve School of Medicine at the Cleveland Clinic.

"We are very pleased that David has joined the Stereotaxis executive team," said Bevil J. Hogg, Chief Executive Officer of Stereotaxis. "He is renowned in the field of cardiac electrophysiology and has extensive experience in the use of robotic navigation systems, including the Stereotaxis Niobe System. Through his authorship of numerous peer-reviewed publications and abstracts, as well as speaking engagements at professional conferences worldwide, David has established himself as an expert in his field. He brings a much-valued perspective as a practicing cardiac electrophysiologist to Stereotaxis' mission to provide the safest, most effective standard of care in the treatment of cardiac arrhythmias."

"I am thrilled to be joining Stereotaxis at this very important time, with the FDA approval of the irrigated tip catheter," said Dr. Burkhardt. "While at the Cleveland Clinic, I had the opportunity to evaluate several new technologies, and performed more than 300 cases with the Stereotaxis Niobe System. I believe that Stereotaxis has the ability to revolutionize the way electrophysiology and interventional procedures are performed."

Dr. Burkhardt is board certified in Internal Medicine, Cardiovascular Medicine and Clinical Cardiac Electrophysiology. He received his Bachelor's and Medical degrees from the University of Louisville. Following graduation, Dr. Burkhardt received special training in Internal Medicine and Cardiovascular Medicine. He spent two years in specialized Cardiac Electrophysiology training at the Cleveland Clinic under Dr. Andrea Natale. After completing his training, he accepted a staff position in Cardiovascular Medicine as an Electrophysiologist at the Cleveland Clinic. His specialties include remote navigation, new technology assessment and optimization of Cardiac Resynchronization Therapy. In 2005, he was appointed Associate Program Director at the Cleveland Clinic. He has authored or co-authored over 30 peer-reviewed publications, 10 book chapters, 100 abstracts and he has presented at numerous national and international professional meetings.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

About Forward Looking Statements

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE  Stereotaxis, Inc.
    -0-                             01/17/2008
    /CONTACT:  company, Jim Stolze, Chief Financial Officer of Stereotaxis,
Inc., +1-314-678-6105; or investors, Doug Sherk, or Jenifer Kirtland,
+1-415-896-6820; or media, Steve DiMattia of EVC Group, Inc., +1-646-201-5445,
all for Stereotaxis, Inc./
    /Web site:  http://www.stereotaxis.com /
    (STXS)

CO:  Stereotaxis, Inc.
ST:  Missouri
IN:  HEA BIO MTC
SU:  PER

NH-AE
-- AQTH027 --
8335 01/17/2008 06:30 EST http://www.prnewswire.com